9 results about "Sigma receptor" patented technology

The use of glutamate 2b receptor antagonists and sigma receptor agonists as antitussives to treat or prevent a cough is disclosed. In preferred embodiments, the glutamate 2b receptor antagonist is ifenprodil or radiprodil. Preferred sigma receptor agonists include fluvoxamine, fluoxetine, excitalpram, and donepezil.

The present disclosure relates, in certain embodiments, to the finding that certain compounds that modulate the activity(ies) of Sigma receptors can be used to disrupt virus lifecycle, infection, and / or dissemination. The compounds contemplated in the disclosure are useful in the prevention, treatment, and / or amelioration of virus infection, either alone or in combination with at least one additional therapeutic agent, which can be an antiviral agent and / or an agent that treats, ameliorates, and / or prevents one or more virus infection symptoms and / or co-morbidities. In certain embodiments, the Sigma receptor is a Sigma-1 receptor (also known as Sigma1) or Sigma-2 receptor (also known as Sigma2 or TMEM97). In certain embodiments, Sigma1 inhibitors / antagonists that cause and / or trigger ER stress and / or autophagy are useful within the methods of the disclosure.

Disclosed herein are compounds and methods of use thereof effective for the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells in the brain and spinal cord, eventually causing loss of muscle strength. The compounds of the disclosure include, cutamesine, a synthetic sigma receptor agonist selective for the 81 receptor, and also a chaperone protein of the central nervous system that plays a key role in the modulation of calcium ions and apoptosis, as well as a sapogenin, such as smilagenin, a non-peptide neurotrophic factor that aids in the reversal of free radical neurotoxicity.

Disclosed in the present invention are an aryl-containing amine compound, a preparation method therefor and a use thereof. The aryl-containing amine compound is represented by formula (I), and has the function of regulating the activity of an NMDA receptor and / or a monoamine transporter and / or a sigma receptor. Thus, the compound can be used for preparing drugs for treating and / or preventing diseases associated with an NMDA receptor and / or a monoamine transporter and / or a sigma receptor, especially central nervous system diseases.

The use of glutamate 2b receptor antagonists and sigma receptor agonists as antitussives to treat or prevent a cough is disclosed. In preferred embodiments, the glutamate 2b receptor antagonist is ifenprodil or radiprodil. Preferred sigma receptor agonists include fluvoxamine, fluoxetine, excitalpram, and donepezil.

The present invention relates to a cyclic derivative, a preparation method therefor and the use thereof. The cyclic derivative can be used as a muscarinic acetylcholine receptor agonist and / or a Sigma receptor agonist, or can be used for treating schizophrenia, Parkinson's disease, Alzheimer's disease, depression and other neuropsychiatric diseases.

The present invention discloses an aryl group-containing amine compound, its preparation method, and use. The aryl group-containing amine compound is represented by formula (I), and has the function of regulating NMDA receptor and / or monoamine transporter and / or sigma receptor activity, and can be used to prepare a medicament for treating and / or preventing diseases associated with NMDA receptors and / or monoamine transporters and / or sigma receptors, particularly central nervous system diseases. JPEG2025538201000350.jpg4951

The invention discloses an aromatic alkylamine ferroptosis and / or Sigma receptor bifunctional inhibitor as well as a preparation method and application thereof. The chemical structural formula of the bifunctional inhibitor is shown in the specification. The bifunctional inhibitor is an aryl alkyl amine compound, can inhibit ferroptosis caused by a ferroptosis inducer, and can reduce the level of active oxygen in cells; the aryl alkyl amine compound can also be used as a Sigma receptor inhibitor, and shows relatively strong affinity with a Sigma receptor; experiments prove that the aryl alkyl amine compound can inhibit the monomer amyloid protein A beta 1-42 from forming multiple polymers of the amyloid protein A beta 1-42. Therefore, the aryl alkyl amine compound provided by the invention can play a very good application value in the treatment of ferroptosis and Sigma receptor related neurological diseases through multiple effects.

Disclosed in the present invention are a bifunctional aromatic alkylamine inhibitor for ferroptosis and / or Sigma receptors, and a preparation method therefor and the use thereof. The bifunctional inhibitor has the chemical structural formula of: (I). The bifunctional inhibitor is an arylalkylamine compound, can inhibit ferroptosis caused by a ferroptosis inducer, and can reduce the intracellular levels of reactive oxygen species. The arylalkylamine compound can also be used as a Sigma receptor inhibitor, showing relatively strong affinity for Sigma receptors. Moreover, it is verified by means of experiments that the arylalkylamine compound can inhibit monomeric amyloid Aβ1-42 from forming aggregates thereof. Therefore, the arylalkylamine compound provided in the present invention has great application value in the treatment, by means of multiple effects, of neurological diseases associated with ferroptosis and Sigma receptors.